scholarly journals Corrigendum to: A Randomized Clinical Trial to Compare Plasmodium falciparum Gametocytemia and Infectivity After Blood-Stage or Mosquito Bite–Induced Controlled Malaria Infection

2020 ◽  
Vol 222 (8) ◽  
pp. 1416-1416
Author(s):  
Manon Alkema ◽  
Isaie J Reuling ◽  
Gerdie M de Jong ◽  
Kjerstin Lanke ◽  
Luc E Coffeng ◽  
...  
Author(s):  
Manon Alkema ◽  
Isaie J Reuling ◽  
Gerdie M de Jong ◽  
Kjerstin Lanke ◽  
Luc E Coffeng ◽  
...  

Abstract Background For malaria elimination efforts, it is important to better understand parasite transmission to mosquitoes and develop models for early-clinical evaluation of transmission-blocking interventions. Methods In a randomized open-label trial, 24 participants were infected by bites from Plasmodium falciparum 3D7-infected mosquitoes (mosquito bite [MB]; n = 12) or by induced blood-stage malaria (IBSM) with the same parasite line (n = 12). After subcurative piperaquine treatment, asexual parasite and gametocytes kinetics were assessed, and mosquito feeding experiments were performed. Results Study procedures were well tolerated. The median peak gametocyte density was 1304/mL (interquartile range, 308–1607/mL) after IBSM, compared with 14/mL (10–64/mL) after MB inoculation (P < .001), despite similar peak asexual parasite densities (P = .48). Peak gametocyte density was correlated with preceding pfap2-g transcripts, indicative of gametocyte commitment (ρ = 0.62; P = .002). Direct feeding assays resulted in mosquito infections from 9 of 12 participants after IBSM versus 0 of 12 after MB inoculation (P < .001). Conclusions We observed a striking effect of inoculation method on gametocyte production, suggesting higher gametocyte commitment after IBSM. Our direct comparison of MB and IBSM establishes the controlled human malaria infection transmission model, using intravenous administration of P. falciparum–infected erythrocytes as a model for early-clinical evaluation of interventions that aim to interrupt malaria transmission. Clinical Trial Registration NCT03454048


PLoS ONE ◽  
2015 ◽  
Vol 10 (4) ◽  
pp. e0117820 ◽  
Author(s):  
Chetan E. Chitnis ◽  
Paushali Mukherjee ◽  
Shantanu Mehta ◽  
Syed Shams Yazdani ◽  
Shikha Dhawan ◽  
...  

PLoS ONE ◽  
2015 ◽  
Vol 10 (9) ◽  
pp. e0137816 ◽  
Author(s):  
Chetan E. Chitnis ◽  
Paushali Mukherjee ◽  
Shantanu Mehta ◽  
Syed Shams Yazdani ◽  
Shikha Dhawan ◽  
...  

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 1676-1676
Author(s):  
Samuel Kirimunda ◽  
Tobias Kinyera ◽  
Martin Ogwang ◽  
Steven J Reynolds ◽  
Moses Joloba ◽  
...  

Abstract Introduction: Infection with Plasmodium falciparum (Pf) malaria is widely accepted as a risk factor for endemic Burkitt lymphoma (eBL), but whether children with eBL are more likely to have detectable blood-stage Pfmalaria parasites and/or report a history of malaria morbidity compared to location-matched control children without eBL is unknown. We investigated this hypothesis in children with eBL (cases) compared to location-matched children without eBL (controls) from the National Cancer Institute (NCI)-sponsored EMBLEM Study. Methods: Cases were children with eBL aged 0-15 years presenting to two hospitals in northern Uganda from 11/2010 to 07/2014 with histologically proven, untreated eBL. Controls were children with similar malaria exposure in the region, including children attending village health centers for minor complaints (pilot health-center controls [PHCs]), at home in 12 randomly selected villages (pilot population controls [PPCs]),and at home in 88 randomly selected villages with matching for the age- and sex-distribution of eBL cases (matched population controls [MPCs]). Cases and controls provided a venous blood sample and questionnaire information on exposure to Pf malaria parasites (mosquito bed net use, insecticide sprays, proximity to a river/swamp, history of treatment for malaria). Blood-stage malaria was evaluated microscopically with giemsa-stained thin and thick blood films and with a commercially available histidine-rich protein (HRPII) antigen-based rapid diagnostic test. The log of thick-film malaria parasite count in cases and controls was compared using the Students t-test. Associations were evaluated by calculating odds ratios (ORs) and 95% confidence intervals (95% CIs) using unconditional logistic regression adjusting for sex, age, ownership/ use of mosquito bed net, and in- or out-patient treatment for malaria. Results:We studied 280 eBL cases (61% male, mean + SD age 7.9 + 3.4 years) and 1619 controls including 171 PHCs (37% male, mean + SD age 7.3 + 4.0 years), 1005 PPCs (48% male, mean + SD age 7.0 + 4.1 years) and 443 MPCs (56% male, mean + SD age 7.5 + 3.3 years). Overall, eBL cases were less likely to own a mosquito bed net than controls (46% versus 67% - 79% in controls, p<0.0001), but among those who owned a mosquito bed net, eBL cases were more likely to have used it the previous night (42% versus 21% - 31% in controls, p<0.0001). Blood-stage malaria infection was detected less frequently in cases compared to controls (Figure 1). In adjusted results, eBL cases were less likely to have current blood-stage malaria infection based on the thin film (OR 0.42 [95% CI 0.26-0.67], p<0.0001) or thick film (OR 0.55 [95% CI 0.38-0.80], p=0.001) and less likely to have had recent infection based on the HRPII rapid diagnostic test (OR 0.31 [95% CI 0.22-0.44], p<0.0001) using all controls combined, with similar results using separate control groups (OR 0.28 – 0.60). Blood-stage malaria parasite count was 0.88 log lower in parasitemic eBL cases than controls (2.24 log versus 3.12 log, p=0.0003). With all controls combined and adjusting for HRPII antigen, the risk of eBL was inversely associated with female sex (OR 0.65 [95% CI 0.46-0.90], p=0.011), ownership of mosquito bed net (OR 0.03 [95% CI 0.01-0.07], p<0.0001), and any inpatient admission for severe malaria (OR 0.56 [95% CI 0.39-0.80], p=0.001) or outpatient treatment for moderate malaria (OR 0.47 [95% CI 0.32-0.69], p<0.0001). The risk of eBL was directly associated with older age (OR 3.1 [95% CI 1.9-5.00] and OR 2.6 [95% CI 1.60-4.40], for 5-9 and 10-15 years versus 0-4 years) and not sleeping under a mosquito net the previous night (OR 10.9 [95% CI 4.34-27.3], p<0.0001). Socioeconomics, spraying insecticides, and proximity to river/swamp did not influence the results. Conclusions: Cases of eBL were unlikely to have Pf malaria parasitemia despite high exposure to mosquitoes and low ownership of bed nets. These results reject the hypothesis that eBL is associated with current or recent blood-stage Pf malaria. They support an alternative hypothesis that children with eBL have superior immunological control of blood-stage infection (Pf elite controller phenotype) and that eBL might be an accident of robust immunological control of blood-stage malaria infection. Further studies are needed to characterize the molecular spectrum of Pf parasites and other mechanisms that drive eBL genesis. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.


2019 ◽  
Vol 71 (6) ◽  
pp. 1481-1490
Author(s):  
Sara A Healy ◽  
Sean C Murphy ◽  
Jen C C Hume ◽  
Lisa Shelton ◽  
Steve Kuntz ◽  
...  

Abstract Background Chemoprophylaxis vaccination with sporozoites (CVac) with chloroquine induces protection against a homologous Plasmodium falciparum sporozoite (PfSPZ) challenge, but whether blood-stage parasite exposure is required for protection remains unclear. Chloroquine suppresses and clears blood-stage parasitemia, while other antimalarial drugs, such as primaquine, act against liver-stage parasites. Here, we evaluated CVac regimens using primaquine and/or chloroquine as the partner drug to discern whether blood-stage parasite exposure impacts protection against homologous controlled human malaria infection. Methods In a Phase I, randomized, partial double-blind, placebo-controlled study of 36 malaria-naive adults, all CVac subjects received chloroquine prophylaxis and bites from 12–15 P. falciparum–infected mosquitoes (CVac-chloroquine arm) at 3 monthly iterations, and some received postexposure primaquine (CVac-primaquine/chloroquine arm). Drug control subjects received primaquine, chloroquine, and uninfected mosquito bites. After a chloroquine washout, subjects, including treatment-naive infectivity controls, underwent homologous, PfSPZ controlled human malaria infection and were monitored for parasitemia for 21 days. Results No serious adverse events occurred. During CVac, all but 1 subject in the study remained blood-smear negative, while only 1 subject (primaquine/chloroquine arm) remained polymerase chain reaction–negative. Upon challenge, compared to infectivity controls, 3/3 chloroquine arm subjects displayed delayed patent parasitemia (P = .01) but not sterile protection, while 3/11 primaquine/chloroquine subjects remained blood-smear negative. Conclusions CVac-primaquine/chloroquine is safe and induces sterile immunity to P. falciparum in some recipients, but a single 45 mg dose of primaquine postexposure does not completely prevent blood-stage parasitemia. Unlike previous studies, CVac-chloroquine did not produce sterile immunity. Clinical Trials Registration NCT01500980.


Sign in / Sign up

Export Citation Format

Share Document